within Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IA07_Technetium99mtcHynicOctr;

model Technetium99mtcHynicOctr
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.388888888888889e-06,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.016,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.012,
    k12 = 1.111111111111111e-06,
    k21 = 1.111111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Technetium99mtcHynicOctreotide</td></tr><tr><td>ATC code:</td><td>V09IA07</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>16</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Technetium (99mTc) HYNIC-octreotide is a radiolabeled somatostatin analog used in nuclear medicine for diagnostic imaging of neuroendocrine tumors and other tumors expressing somatostatin receptors. It is administered as a single intravenous dose and is widely approved and utilized in SPECT imaging procedures.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimate for typical adult subjects undergoing diagnostic imaging; no specific published compartmental model parameters found for this tracer, values here are estimated based on published imaging and excretion profiles.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V09IA07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Technetium99mtcHynicOctr;
